Telescope Innovations Presents Results of Third Fiscal Quarter 2025

Financial Performance - Telescope Innovations Corp. reported revenues of CAD 1.4 million for the fiscal quarter ended May 31, 2025, compared to CAD 1.2 million for the same quarter in FY 2024, reflecting a growth of approximately 14% [1][7] - The company incurred an adjusted EBITA loss of CAD 0.1 million, which is an increase from a loss of CAD 0.05 million in the comparable quarter of FY 2024 [1][7] - Total expenses for the quarter were CAD 1.9 million, up from CAD 1.4 million in the same quarter of FY 2024 [7] Operational Highlights - Telescope shipped its first battery-grade lithium sulfide (Li₂S) samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process [4] - The company is part of the Arkansas Lithium Technology Accelerator, focusing on innovating the battery supply chain [4] - The DirectInject-LC™ product experienced significant growth, with sales and order pipelines more than doubling compared to Q3 2024 [7] Strategic Partnerships - Telescope is collaborating with Pfizer to develop a "Phase 1" Self-Driving Lab (SDL) platform, which aims to enhance chemistry research efficiency by up to 100 times compared to traditional methods [7] - The company is working with Mettler Toledo on a global distribution campaign, executing 11 application feasibility studies and participating in lead-generating events [7] Company Overview - Telescope Innovations Corp. focuses on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as robotic platforms and artificial intelligence [6]